Intellia continues to advance in vivo candidate
At the Intellia Therapeutics, Inc. operational highlights and financial results for the first quarter ended 31 March 2022, President and CEO John Leonard, M.D., says: “We continue to advance our second in vivo candidate, NTLA-2002, which benefits from the modularity of our platform. We look forward to another important clinical milestone in the second half of [...]